Institute of Clinical Chemistry, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Clin Sci (Lond). 2012 Apr;122(8):385-96. doi: 10.1042/CS20110482.
BA (bile acid) formation is considered an important final step in RCT (reverse cholesterol transport). HDL (high-density lipoprotein) has been reported to transport BAs. We therefore investigated the effects of monogenic disturbances in human HDL metabolism on serum concentrations and lipoprotein distributions of the major 15 BA species and their precursor C4 (7α-hydroxy-4-cholesten-3-one). In normolipidaemic plasma, approximately 84%, 11% and 5% of BAs were recovered in the LPDS (lipoprotein-depleted serum), HDL and the combined LDL (low-density lipoprotein)/VLDL (very-low-density lipoproteins) fraction respectively. Conjugated BAs were slightly over-represented in HDL. For C4, the respective percentages were 23%, 21% and 56% (41% in LDL and 15% in VLDL) respectively. Compared with unaffected family members, neither HDL-C (HDL-cholesterol)-decreasing mutations in the genes APOA1 [encoding ApoA-I (apolipoprotein A-I], ABCA1 (ATP-binding cassette transporter A1) or LCAT (lecithin:cholesterol acyltransferase) nor HDL-C-increasing mutations in the genes CETP (cholesteryl ester transfer protein) or LIPC (hepatic lipase) were associated with significantly different serum concentrations of BA and C4. Plasma concentrations of conjugated and secondary BAs differed between heterozygous carriers of SCARB1 (scavenger receptor class B1) mutations and unaffected individuals (P<0.05), but this difference was not significant after correction for multiple testing. Moreover, no differences in the lipoprotein distribution of BAs in the LPDS and HDL fractions from SCARB1 heterozygotes were observed. In conclusion, despite significant recoveries of BAs and C4 in HDL and despite the metabolic relationships between RCT and BA formation, monogenic disorders of HDL metabolism do not lead to altered serum concentrations of BAs and C4.
BA(胆汁酸)的形成被认为是 RCT(胆固醇逆转运)的重要终末步骤。HDL(高密度脂蛋白)已被报道可转运 BA。因此,我们研究了人类 HDL 代谢中单基因突变对主要 15 种 BA 及其前体 C4(7α-羟基-4-胆甾烷-3-酮)的血清浓度和脂蛋白分布的影响。在正常脂质血症血浆中,BA 约有 84%、11%和 5%分别在 LPDS(脂蛋白 depleted serum,脂蛋白耗尽血清)、HDL 和 LDL/ VLDL(极低密度脂蛋白)的组合部分中被回收。结合 BA 在 HDL 中略有过表达。对于 C4,相应的百分比分别为 23%、21%和 56%(41%在 LDL 和 15%在 VLDL)。与未受影响的家族成员相比,APOA1(编码载脂蛋白 A-I)、ABCA1(ATP 结合盒转运蛋白 A1)或 LCAT(卵磷脂:胆固醇酰基转移酶)基因中降低 HDL-C 的突变、CETP(胆固醇酯转移蛋白)或 LIPC(肝脂肪酶)基因中升高 HDL-C 的突变均与 BA 和 C4 的血清浓度无显著差异相关。载脂蛋白 A-I 基因突变的杂合子携带者和未受影响的个体之间,次级和结合 BA 的血浆浓度存在差异(P<0.05),但经多次检验校正后,这种差异无统计学意义。此外,未观察到载脂蛋白 A-I 基因突变的杂合子 LPDS 和 HDL 部分 BA 的脂蛋白分布存在差异。总之,尽管 BA 和 C4 在 HDL 中有显著的回收,尽管 RCT 和 BA 形成之间存在代谢关系,但 HDL 代谢的单基因疾病不会导致 BA 和 C4 的血清浓度改变。